Article

BCAN Applauds Bill to Provide Long-Overdue Help to Veteran Bladder Cancer Patients

The Bladder Cancer Advocacy Network (BCAN) is pleased that the U.S. Senate voted overwhelmingly to approve the National Defense Authorization Act (NDAA) which contains a critical provision that will help veterans who were exposed to Agent Orange and later developed bladder cancer.

The Bladder Cancer Advocacy Network (BCAN) is pleased that the U.S. Senate voted overwhelmingly to approve the National Defense Authorization Act (NDAA) which contains a critical provision that will help veterans who were exposed to Agent Orange and later developed bladder cancer.

“By passing this bill, veteran bladder cancer patients could get the additional medical benefits that they have long deserved after having nobly served their country,” said Andrea Maddox-Smith, BCAN’s Chief Executive Officer. “We are deeply grateful to Senator Jon Tester (D-MT) and Rep. Josh Harder (D-CA) for leading efforts in their respective chambers to pass a critical amendment that will help so many veterans suffering from bladder cancer.”

Currently, veterans have to overcome significant bureaucratic hurdles to get their bladder cancer treatments covered. If this bill is signed into law, bladder cancer will now be presumptively connected to their service.

Over the last several years, BCAN has worked with Congressional allies and like-minded health and service organizations to advocate for proper healthcare coverage for veterans who contracted bladder cancer.

With the bill overwhelmingly passing both the House and Senate, it now moves to the President for his signature.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of doctor.
Image of man.
Image of man with black hair.
Image of man.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Image of man with black hair.
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Image of bald man.
Related Content